Immune Pharmaceuticals Inc
OTC:IMNPQ
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Immune Pharmaceuticals Inc
Current Portion of Long-Term Debt
Immune Pharmaceuticals Inc
Current Portion of Long-Term Debt Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
Immune Pharmaceuticals Inc
OTC:IMNPQ
|
Current Portion of Long-Term Debt
$3.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
147%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Current Portion of Long-Term Debt
$10.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
45%
|
CAGR 10-Years
88%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Current Portion of Long-Term Debt
$3.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Current Portion of Long-Term Debt
$4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
1%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Immune Pharmaceuticals Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
3.3m
USD
Based on the financial report for Dec 31, 2017, Immune Pharmaceuticals Inc's Current Portion of Long-Term Debt amounts to 3.3m USD.
What is Immune Pharmaceuticals Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
147%
Over the last year, the Current Portion of Long-Term Debt growth was 18%. The average annual Current Portion of Long-Term Debt growth rates for Immune Pharmaceuticals Inc have been 18% over the past three years , 147% over the past five years .
You don't have any saved screeners yet
